Online inquiry

IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13763MR)

This product GTTS-WQ13763MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Sarcopenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13763MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2007MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ4278MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ2621MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ7786MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ9370MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ15191MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ1199MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ5806MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CFZ-533
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW